10/04/2026
In a large multicenter retrospective cohort study, males aged 9 to 26 years who received at least one dose of the 9-valent human papillomavirus ( ) vaccine demonstrated a lower risk of composite —including head and neck, esophageal, a**l, and pe**le cancers—compared with unvaccinated males.
The association persisted across both adolescent (9-14 years) and young adult (15-26 years) groups, supporting the benefit of sex-neutral HPV vaccination strategies for reducing cancer burden in males.
https://ja.ma/47PDiU4